PracticeUpdate: What significant area of evaluation regarding NSCLC treatment did the ZENITH20-4 trial address at ESMO 2021?
Dr. Henry: LBA 46: “Efficacy and safety of poziotinib, it's a (TKI) tyrosine kinase inhibitor, poziotinib. In treatment-naïve non-small cell lung cancer with a HER2 or EGFR exon 20 mutation.” So, a pretty rare group, HER2 or EGFR exon 20, that's the key here. Another unmet need, driver-mutated lung cancer they found for this study. These patients were enrolled who were either treatment naïve or experienced, and either had the HER2 exon 20 or the EGFR exon 20. This study, LBA 46, only reporting the HER2 exon 20 driver mutated in 48 patients. The doses were 16 mg a day oral or 8 mg twice a day. Primary endpoint overall response rate, 44%. So again, niche market, niche patient, small numbers, but if we're testing for everything either on biopsy of tissue or liquid biopsy you find, in this case, the HER2 exon 20. This patient report was previously untreated.
A rather impressive response rate with a pill only.